Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00083

Target Information
NameTopoisomerase IV    
Type of targetSuccessful target    
SynonymsTopo IV    
DiseaseBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
Drug(s)BesifloxacinApprovedBacterial conjunctivitis
GatifloxacinApprovedRespiratory tract infections[6]
GatifloxacinApprovedRespiratory tract infections[6]
LevofloxacinApprovedBacterial infections[7]
MoxifloxacinApprovedBacterial infections[8]
SparfloxacinApprovedBacterial infections[7]
ciprofloxacinApprovedBacterial infections[9]
BioChemical ClassIsomerases    
EC NumberEC 5.99.1.-
Target ValidationClick to Find Target Validation Information.    
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. To Reference
Ref 2ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae. J Bacteriol. 2003 Oct;185(20):6137-46. To Reference
Ref 3Overexpression and purification of bacterial topoisomerase IV. Methods Mol Biol. 1999;94:163-9. To Reference
Ref 4Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5. To Reference
Ref 5Quinolone resistance in Escherichia coli. Vet Res. 2001 May-Aug;32(3-4):275-84. To Reference
Ref 6Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. To Reference
Ref 7DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. To Reference
Ref 8Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem Pharmacol. 2008 Mar 15;75(6):1272-81. Epub 2007 Dec 3. To Reference
Ref 9Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother. 2008 Jun;52(6):2196-204. Epub 2008 Feb 25. To Reference
Ref 10Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543